Campylobacter jejuni disrupts protective Toll-like receptor 9 signaling in colonic epithelial cells and increases the severity of dextran sulfate sodium-induced colitis in mice.
Inflammatory bowel disease (IBD) is characterized by chronic intestinal inflammation associated with a dysregulated immune response to commensal bacteria in susceptible individuals. The relapse of IBD may occur following an infection with Campylobacter jejuni. Apical epithelial Toll-like receptor 9 (TLR9) activation by bacterial DNA is reported to maintain colonic homeostasis. We investigated whether a prior C. jejuni infection disrupts epithelial TLR9 signaling and increases the severity of disease in a model of mild dextran sulfate sodium (DSS) colitis in mice. In a further attempt to identify mechanisms, T84 monolayers were treated with C. jejuni followed by a TLR9 agonist. Transepithelial resistance (TER) and dextran flux across confluent monolayers were monitored. Immunohistochemistry, Western blotting, and flow cytometry were used to examine TLR9 expression. Mice colonized by C. jejuni lacked any detectable pathology; however, in response to low levels of DSS, mice previously exposed to C. jejuni exhibited significantly reduced weight gain and increased occult blood and histological damage scores. Infected mice treated with DSS also demonstrated a significant reduction in levels of the anti-inflammatory cytokine interleukin-25. In vitro studies indicated that apical application of a TLR9 agonist enhances intestinal epithelial barrier function and that this response is lost in C. jejuni-infected monolayers. Furthermore, infected cells secreted significantly more CXCL8 following the basolateral application of a TLR9 agonist. Surface TLR9 expression was reduced in C. jejuni-infected monolayers subsequently exposed to a TLR9 agonist. In conclusion, infection by C. jejuni disrupts TLR9-induced reinforcement of the intestinal epithelial barrier, and colonization by C. jejuni increases the severity of mild DSS colitis.
Department of Biological Sciences and Inflammation Research Network, University of Calgary, Calgary, Alberta, Canada.
Jennifer R
JR
O'Hara
Troy D
TD
Feener
Carrie D
CD
Fischer
Andre G
AG
Buret
D000818:Animals; D002169:Campylobacter Infections / Q000276:immunology* / Q000378:metabolism / Q000473:pathology; D016123:Campylobacter jejuni / Q000276:immunology / Q000378:metabolism* / Q000472:pathogenicity*; D002460:Cell Line; D003092:Colitis / Q000139:chemically induced / Q000473:pathology / Q000503:physiopathology*; D003106:Colon / Q000276:immunology* / Q000382:microbiology / Q000473:pathology; D004269:DNA, Bacterial / Q000378:metabolism; D016264:Dextran Sulfate; D004847:Epithelial Cells / Q000276:immunology* / Q000382:microbiology / Q000473:pathology; D020381:Interleukin-17 / Q000096:biosynthesis; D016209:Interleukin-8 / Q000096:biosynthesis / Q000378:metabolism; D007413:Intestinal Mucosa / Q000276:immunology / Q000382:microbiology / Q000473:pathology; D051379:Mice; D008810:Mice, Inbred C57BL; D015398:Signal Transduction; D051217:Toll-Like Receptor 9 / Q000819:agonists / Q000378:metabolism*
D004269:DNA, Bacterial; D020381:Interleukin-17; D016209:Interleukin-8; C495370:Tlr9 protein, mouse; D051217:Toll-Like Receptor 9; D016264:Dextran Sulfate